{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T11:56:54Z","timestamp":1763726214375},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s10557-008-6156-1","type":"journal-article","created":{"date-parts":[[2008,12,9]],"date-time":"2008-12-09T19:57:31Z","timestamp":1228852651000},"page":"171-181","source":"Crossref","is-referenced-by-count":23,"title":["The Rationale and Design of the Perindopril Genetic Association Study (PERGENE): A Pharmacogenetic Analysis of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Stable Coronary Artery Disease"],"prefix":"10.1007","volume":"23","author":[{"name":"On behalf of the EUROPA-PERGENE investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Brugts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P. M.","family":"de Maat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. C. M.","family":"Witteman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"van Duijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. G.","family":"Uitterlinden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Remme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H. J.","family":"Danser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Simoons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,10]]},"reference":[{"key":"6156_CR1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moye LA, SAVE Investigators, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669\u201377.","journal-title":"N Engl J Med"},{"key":"6156_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD investigators","year":"1991","unstructured":"The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"6156_CR3","first-page":"821","volume":"342","author":"The Acute Infarction Ramipril Efficacy (AIRE) study investigators","year":"1993","unstructured":"The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821\u20138.","journal-title":"Lancet"},{"key":"6156_CR4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)09374-X","volume":"354","author":"C Torp-Pedersen","year":"1999","unstructured":"Torp-Pedersen C, Kober L, TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999;354:9\u201312.","journal-title":"Lancet"},{"key":"6156_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation study investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145\u201353.","journal-title":"N Engl J Med"},{"key":"6156_CR6","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","volume":"351","author":"The PEACE Trial Investigators","year":"2004","unstructured":"The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058\u201368.","journal-title":"N Engl J Med"},{"key":"6156_CR7","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease investigators","year":"2003","unstructured":"The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782\u20138.","journal-title":"Lancet"},{"key":"6156_CR8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","volume":"27","author":"The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology","year":"2006","unstructured":"The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris. Eur Heart J 2006;27:1341\u201381.","journal-title":"Eur Heart J"},{"key":"6156_CR9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0021-9150(98)90209-X","volume":"140","author":"D Wood","year":"1998","unstructured":"Wood D, DeBacker G, Faergam O, Graham I, Mancia G, Py\u00f6r\u00e4l\u00e4 K, and the task force. Prevention of coronary disease in clinical practice: recommendation of the second Joint Task Force of European and other societies on Coronary Prevention. Atherosclerosis 1998;140:99\u2013270.","journal-title":"Atherosclerosis"},{"key":"6156_CR10","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0735-1097(02)02848-6","volume":"41","author":"RJ Gibbons","year":"2003","unstructured":"Gibbons RJ, Abrams J, Chatterjee K, et al. ACC\/AHA 2002 guideline update for the management of patients with chronic stable angina\u2014summary article: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159\u201368.","journal-title":"J Am Coll Cardiol"},{"key":"6156_CR11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","volume":"366","author":"B Dahl\u00f6f","year":"2005","unstructured":"Dahl\u00f6f B, Sever PS, \u00d6stergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895\u2013906.","journal-title":"Lancet"},{"issue":"358","key":"6156_CR12","first-page":"1033","volume":"200","author":"PROGRESS Collaborative Group","year":"2001","unstructured":"PROGRESS Collaborative Group. Randomised trial of a perindopril based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;200(358):1033\u201341.","journal-title":"Lancet"},{"key":"6156_CR13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archinte.166.6.659","volume":"166","author":"The PREAMI Investigators","year":"2006","unstructured":"The PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome. Results of the Randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006;166:659\u201366.","journal-title":"Arch Intern Med"},{"key":"6156_CR14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","volume":"370","author":"ADVANCE Collaborative Group","year":"2007","unstructured":"ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007;370:829\u201340.","journal-title":"Lancet"},{"key":"6156_CR15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10557-007-6041-3","volume":"21","author":"ML Bots","year":"2007","unstructured":"Bots ML, Remme WJ, L\u00fcscher TF, et al. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial. Cardiovasc Drugs Ther 2007;21:269\u201379.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6156_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.amjcard.2007.02.073","volume":"100","author":"GA Rodriguez-Granillo","year":"2007","unstructured":"Rodriguez-Granillo GA, Vos J, De Feyter PJ. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril\u2019s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007;100:159\u201363.","journal-title":"Am J Cardiol"},{"key":"6156_CR17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cardiores.2006.10.021","volume":"73","author":"C Ceconi","year":"2007","unstructured":"Ceconi C, Fox KM, Ferrari R, et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007;73:237\u201346.","journal-title":"Cardiovasc Res"},{"key":"6156_CR18","doi-asserted-by":"crossref","unstructured":"Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML. for the EUROPA investigators. Secondary prevention of coronary disease with ACE inhibition\u2014does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drugs Ther 2009;23 (this issue).","DOI":"10.1007\/s10557-008-6143-6"},{"key":"6156_CR19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(06)69201-5","volume":"368","author":"GR Dagenais","year":"2006","unstructured":"Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581\u20138.","journal-title":"Lancet"},{"key":"6156_CR20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/eurheartj\/ehi809","volume":"27","author":"JW Deckers","year":"2006","unstructured":"Deckers JW, Goedhart DM, Boersma E, et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006;27:796\u2013801.","journal-title":"Eur Heart J"},{"key":"6156_CR21","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.jacc.2007.08.029","volume":"50","author":"JJ Brugts","year":"2007","unstructured":"Brugts JJ, Boersma E, Chonchol M, et al. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007;50:2148\u201355.","journal-title":"J Am Coll Cardiol"},{"key":"6156_CR22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/HCO.0b013e3283007ba6","volume":"23","author":"JJ Brugts","year":"2008","unstructured":"Brugts JJ, de Maat M, den Uil CA, et al. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr Opin Cardiol 2008;23:296\u2013301.","journal-title":"Curr Opin Cardiol"},{"key":"6156_CR23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000159124","volume":"112","author":"JJ Brugts","year":"2008","unstructured":"Brugts JJ, den Uil CA, de Maat M, Danser AHJ. The renin\u2013angiotensin\u2013aldosteron system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 2008;112:303\u201312.","journal-title":"Cardiology"},{"key":"6156_CR24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1011131130922","volume":"15","author":"AH Gomma","year":"2001","unstructured":"Gomma AH, Fox KM, for the EUROPA investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001;15:169\u201379.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6156_CR25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1538-7836.2003.00216.x","volume":"1","author":"RJ Nederhand","year":"2003","unstructured":"Nederhand RJ, Droog S, Kluft C, Simoons ML, de Maat MP. Logistics and quality control for DNA sampling in large multicenter studies. J Thromb Haemost 2003;1:987\u201391.","journal-title":"J Thromb Haemost"},{"key":"6156_CR26","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJM199810293391804","volume":"339","author":"JV Gainer","year":"1998","unstructured":"Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285\u201392.","journal-title":"N Engl J Med"},{"key":"6156_CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0014-2999(00)00823-2","volume":"410","author":"AHJ Danser","year":"2000","unstructured":"Danser AHJ, Schunkert H. Renin\u2013angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000;410:303\u201316.","journal-title":"Eur J Pharmacol"},{"key":"6156_CR28","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2165\/00003495-200464160-00006","volume":"64","author":"H Schelleman","year":"2004","unstructured":"Schelleman H, Stricker BH, De Boer A, et al. Drug\u2013gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 2004;64:1801\u201316.","journal-title":"Drugs"},{"key":"6156_CR29","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.HYP.0000088322.85804.96","volume":"42","author":"SB Harrap","year":"2003","unstructured":"Harrap SB, Tzourio C, Cambien F. The ACE gene I\/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003;42:297.","journal-title":"Hypertension"},{"key":"6156_CR30","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-199816121-00005","volume":"16","author":"AH Danser","year":"1998","unstructured":"Danser AH, Derkx FH, Hense HW, Jeunemaitre X, Riegger GA, Schunkert H. Angiotensinogen (M235T) and angiotensin converting enzyme (I\/D) polymorphisms in association with plasma renin and prorenin levels. J Hypertens 1998;16:1879\u201383.","journal-title":"J Hypertens"},{"key":"6156_CR31","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1161\/hy1101.096114","volume":"38","author":"J Deinum","year":"2001","unstructured":"Deinum J, van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001;38:1278\u201381.","journal-title":"Hypertension"},{"key":"6156_CR32","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1161\/01.CIR.0000128696.12245.57","volume":"109","author":"WW Batenburg","year":"2004","unstructured":"Batenburg WW, Garrelds IM, Bernasconi CC, et al. Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 2004;109:2296\u2013301.","journal-title":"Circulation"},{"key":"6156_CR33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/hrt.2005.086728","volume":"93","author":"A Briggs","year":"2007","unstructured":"Briggs A, Mihaylova B, Sculpher M, EUROPA-trial investigators, et al. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart 2007;93:1081\u20136.","journal-title":"Heart"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-008-6156-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T06:55:00Z","timestamp":1550300100000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-008-6156-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,10]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["6156"],"URL":"https:\/\/doi.org\/10.1007\/s10557-008-6156-1","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2008,12,10]]}}}